PDE4 inhibition: A novel approach for the treatment of inflammatory bowel disease

Trends in Pharmacological Sciences

Volumn 25, Issue 8, 2004, Pages 430-436

  Banner, Katharine H ^a   Trevethick, Michael A ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 (CYCLOPENTYLOXY) 4 METHOXYPHENYL] 3 (1,3 DIOXO 1,3 DIHYDRO 2H ISOINDOL 2 YL)PROPANAMIDE; AMINOSALICYLIC ACID; AROFYLLINE; CC 1088; CILOMILAST; CYCLIC AMP; DEXTRAN SULFATE; INDOMETACIN; INFLIXIMAB; MESOPRAM; METHYLPREDNISOLONE; PENTOXIFYLLINE; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PREDNISOLONE; ROFLUMILAST; ROLIPRAM; SALICYLIC ACID; STEROID; TETOMILAST; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CELL ACTIVATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CROHN DISEASE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; HUMAN; IMMUNOMODULATION; INFLAMMATION; INFLAMMATORY CELL; LEUKOCYTE; NAUSEA; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; RECTUM HEMORRHAGE; REVIEW; SIDE EFFECT; ULCER; ULCERATIVE COLITIS; VASCULITIS; VOMITING; WEIGHT REDUCTION;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; AMINOPYRIDINES; ANIMALS; ANTI-INFLAMMATORY AGENTS; BENZAMIDES; BRONCHODILATOR AGENTS; CARBOXYLIC ACIDS; CYCLOPROPANES; ENZYME INHIBITORS; HUMANS; INFLAMMATORY BOWEL DISEASES; NITRILES;

EID: 3242804420     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2004.06.008     Document Type: Review

References (58)

1. Torphy T.J. Phosphodiesterase isozymes: molecular targets for novel anti-asthma agents. Am. J. Respir. Crit. Care Med. 157:1998;351-370
2. Soderling S.H., Beavo J.A. Regulation of cAMP and cGMP signalling: new phosphodiesterases and new functions. Curr. Opin. Cell Biol. 12:2000;174-179
3. Beavo J., et al. Multiple cyclic nucleotide phosphodiesterases. Mol. Pharmacol. 46:1994;399-405
4. Houslay M.D., et al. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: Intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and anti-depressant actions. August J.T.,, et al. Advances in Pharmacology. 1998;225-342 Academic Press
5. Obernolte R., et al. Multiple splice variants of phosphodiesterase PDE4C cloned from human lung and testis. Biochim. Biophys. Acta. 1353:1997;287-297
6. Spina D. Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. Drugs. 63:2003;2575-2594
7. Keighley M.R.B., Stockbrugger R.W. Inflammatory bowel disease. Aliment. Pharmacol. Ther. 18:(Suppl. 3):2003;66-70
8. Podolsky D.K. Inflammatory bowel disease. New Engl. J. Med. 347:2002;417-429
9. Blam M.E. Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives. Am. J. Gastroenterol. 96:2001;1977-1997
10. Neurath M.F., et al. The role of Th1/Th2 polarization in mucosal immunity. Nat. Med. 8:2002;567-573
11. Farrell R.J., et al. Glucocorticoid resistance in inflammatory bowel disease. J. Endocrinol. 178:2003;339-346
12. van Deventer S.J. Small therapeutic molecules for the treatment of inflammatory bowel disease. Gut. 50:(Suppl. 3):2002;47-53
13. Elson C.O. The basis of current and future therapy for inflammatory bowel disease. Am. J. Med. 100:1996;656-662
14. O'Connell J., et al. Interferon-γ sensitises colonic epithelial cell lines to physiological and therapeutic inducers of colonocyte apoptosis. J. Cell. Physiol. 185:2000;331-338
15. Plevy S.E., et al. A role for TNF- alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J. Immunol. 159:1997;6276-6282
16. Sullivan G.W. Activation of A2a adenosine receptors inhibits expression of alpha4beta 1 integrin (very late antigen-4) on stimulated human neutrophils. J. Leukoc. Biol. 75:2004;127-134
17. Pender S.L.F. A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production. J. Immunol. 160:1998;4098-4103
18. Horie Y., et al. Induction of major histocompatability complex class II antigens on human colonic epithelium by interferon-gamma, tumour necrosis factor-alpha, and interleukin-2. J. Gastroenterol. 33:1998;39-47
19. Eckmann L. Differential cytokine expression by human intestinal epithelial cells lines: regulated expression of interleukin-8. Gastroenterology. 105:1993;1689-1697
20. Wedemeyer J. Enhanced production of monocyte chemotactic protein 3 in inflammatory bowel disease mucosal. Gut. 44:1999;629-635
21. Rutgeerts P., et al. Efficacy and safety of re-treatment with anti-TNF-α antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 117:1999;761-769
22. Van Dullemen H.M., et al. Treatment of therapy resistant perineal metastatic Crohn's disease after protectomy using anti-tumour necrosis factor chimeric monoclonal antibody, ca2. Dis. Colon Rectum. 41:1998;98-102
23. Powrie F. T cells in inflammatory bowel disease: Protective and pathogenic roles. Immunity. 3:1995;171-174
24. Semmler J. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumour necrosis factor-α production by human mononuclear cells. Int. J. Immunopharmacol. 15:1993;409-413
25. Prehn J.L., et al. Potent inhibition of cytokine production from intestinal lamina propria T cells by phosphodiesterase-4 inhibitory thalidomide analogues. J. Clin. Immunol. 21:2001;357-364
26. Eigler A., et al. Anti-inflammatory activities of cAMP elevating agents: enhancement of interleukin-10 synthesis and concurrent suppression of TNF-α production. J. Leukoc. Biol. 63:1998;101-107
27. 2 to the anti-proliferative effect of phosphodiesterase 4 inhibitors in human mononuclear cells. Biochem. Pharmacol. 58:1999;1487-1495
28. Kasyapa C.S., et al. Regulation of IL-15 stimulated TNF-alpha production by rolipram. J. Immunol. 163:1999;2836-2843
29. Hidi R., et al. Phosphodiesterase and cyclic adenosine monophosphate-dependent inhibition of T-lymphocyte chemotaxis. Eur. Respir. J. 15:2000;342-349
30. Kohyama T., et al. Phosphodiesterase 4 inhibitor cilomilast inhibits fibroblast-mediated collagen gel degradation induced by tumour necrosis factor-alpha and neutrophil elastase. Am. J. Respir. Cell Mol. Biol. 27:2002;487-494
31. Loher F., et al. The specific type-4 phosphodiesterase inhibitor mesopram alleviates experimental colitis in mice. J. Pharmacol. Exp. Ther. 305:2003;549-556
32. Maeda T., et al. Effects of intravenous or oral administration of OPC-6535 in a rat model of 2,4,6,-trinitro benzene sulfonic acid (TNBS)-induced colitis. Gut. 41:(Suppl. 3):1997;A112
33. Puig J., et al. Curative effects of phosphodiesterase 4 inhibitors in dextran sulfate sodium-induced colitis in the rat. Gastroenterology. 114:1998;G4357
34. Videla S., et al. Selective inhibition of phosphodiesterase type IV ameliorates chronic colitis and prevents intestinal fibrosis. Gastroenterology. 114:1998;G4542
35. Hartmann G., et al. Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice. J. Pharmacol. Exp. Ther. 292:2000;22-30
36. Axelsson L.G., et al. Experimental colitis induced by dextran sulphate sodium in mice: beneficial effects of sulphasalazine and olsalazine. Aliment. Pharmacol. Ther. 12:1998;925-934
37. Murthy S., et al. Combination therapy of pentoxifylline and TNF-α monoclonal antibody in dextran sulphate-induced mouse colitis. Aliment. Pharmacol. Ther. 13:1999;251-260
38. Diaz-Granados N., et al. Dextran sulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity. Am. J. Pathol. 156:2000;2169-2177
39. Anthony A., et al. Similarities between ileal Crohn's disease and indomethacin experimental jejunal ulcers in the rat. Aliment. Pharmacol. Ther. 14:2000;241-245
40. Kumar R., et al. Inhibition of inflammation and remodelling by roflumilast and dexamethasone in murine chronic asthma. J. Pharmacol. Exp. Ther. 307:2003;349-372
41. Gamble E., et al. Anti-inflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 168:2003;976-978
42. Bauditz J., et al. Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease. Gut. 40:1997;470-474
43. Corral L.G., et al. Differential Cytokine Modulation and T Cell Activation by Two Distinct Classes of Thalidomide Analogues That Are Potent Inhibitors of TNFα J. Immunol. 163:1999;380-386
44. Hatoum O.A., et al. The vascular contribution in the pathogenesis of inflammatory bowel disease. Am. J. Physiol. 285:2003;H1791-H1796
45. Wakefield A.J., et al. Granulomatous vasculitis in Crohn's disease. Gastroenterology. 100:1991;1279-1287
46. Tsuji M., et al. Colonic mucosal hemodynamics and tissue oxygenation in patients with ulcerative colitis. J. Gastroenterol. 30:1995;183-188
47. Appleyard C.B., et al. Temporal changes of colonic blood flow and tissue damage in an animal model of colitis. Dig. Dis. Sci. 44:1999;431-438
48. Kern F., et al. The motility of the distal colon in non specific ulcerative colitis. Gastroenterology. 19:1951;492-503
49. Goultston S.J.M., McGovern V.J. The nature of benign strictures in ulcerative colitis. New Engl. J. Med. 281:1969;290-295
50. Takeuchi K., et al. Increased microvascular permeability and lesion formation during gastric hypermotility caused by indomethacin and 2-deosxy-glucose in the rat. J. Clin. Gastroenterol. 12:(Suppl. 1):1990;S76-S84
51. McLean P.G., Couper I.M. Further investigation unto the signal transduction mechanism of the 5HT-4 like receptor in the circular smooth muscle of the human colon. Br. J. Pharmacol. 118:1996;1058-1064
52. Jones O.M., et al. Phosphodiesterase inhibitors cause relaxation of the internal anal sphincter in vitro. Dis. Colon Rectum. 45:2002;530-536
53. Anthony A. Review Article: β3 adrenoceptor agonists - future anti-inflammatory drugs for the gastro intestinal tract. Aliment. Pharmacol. Ther. 10:1996;859-863
54. Slim R.M., et al. Effect of dexamethasone on the metabonomics profile associated with phosphodiesterase inhibitor induced vascular lesions in rats. Toxicol. Appl. Pharmacol. 183:2002;108-109
55. 2 adrenoceptor mediated anaesthesia: a behavioural surrogate of emesis. J. Clin. Invest. 110:2002;1045-1052
56. Rochibaud A., et al. Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret. Neuropharmacology. 38:1999;289-297
57. Navarro F.N., Hanauer S.B. Treatment of inflammatory bowel disease: safety and tolerability issues. Am. J. Gastroenterol. 98:2003;S18-S23
58. Miyakoda G., et al. Effects of intravenous or oral administration of OPC-6535 in a rat model of dextran sodium sulfate (DSS)-induced colitis. Gut. 41:1997;A227